Novonesis Leads Europe's Stoxx 600 on Sales Beat, Guidance Raise

Stock in the company—which develops enzymes, probiotics and other biological products—jumped after its grew 9%, ahead of consensus estimates.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。